Zacks Research Predicts Aethlon Medical Q1 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Research analysts at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for Aethlon Medical in a research note issued to investors on Thursday, June 11th. Zacks Research analyst M. Marin expects that the medical equipment provider will earn ($0.81) per share for the quarter. The consensus estimate for Aethlon Medical’s current full-year earnings is ($0.98) per share. Zacks Research also issued estimates for Aethlon Medical’s Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.23) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $2.00 on Tuesday. Aethlon Medical has a 1 year low of $1.36 and a 1 year high of $27.40. The stock’s 50 day simple moving average is $2.21 and its two-hundred day simple moving average is $2.45. The company has a market cap of $3.14 million, a price-to-earnings ratio of -0.14 and a beta of 1.49.

Institutional Trading of Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new stake in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.